Cartesian Therapeutics, Inc. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
Cartesian Therapeutics, Inc. (RNAC) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $15.80 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2021-11-09
- 2021-09-30: Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 9 month $15.80M.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 9 month |
|---|---|
| 2021-09-30 | $15.80M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |